Sarcopenia Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsight

A detailed review of historical and forecasted Sarcopenia market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sarcopenia market. An all-inclusive account of both the current and emerging therapies for Sarcopenia, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

Sarcopenia Overview
Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.

Download a Sample Copy of the Market Report- https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Highlights of the Sarcopenia Market Report
• As per Society on Sarcopenia, Cachexia and Wasting Disorders, the prevalence of Sarcopenia ranges from 15% at 65 years to 50% at 80 years in humans, with normal aging associated with a 1-2% muscle loss beyond the age of 50 years.
• As per DelveInsight estimates, the total prevalent population of Sarcopenia in the 7MM was found to be 33,321,576 in 2017.
• According to DelveInsight, males are affected more as compared to females in case of Sarcopenia.

Sarcopenia Epidemiology Insights
Current definitions of Sarcopenia are only newly developed and still not entirely accepted. Reported prevalence rates of Sarcopenia vary significantly due to differing definitions, tools of diagnosis, and patient populations. Estimates range from 10% in individuals >65 years of age, rising to 30% in men over 80.

Sarcopenia Epidemiology Segmentation in the 7MM
• Sarcopenia Prevalent Cases
• Sarcopenia Prevalence by Gender

Sarcopenia Etiology
The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distribution), reduced anabolic hormone levels, muscle disuse, and inflammation, driven by environmental, genetic and behavioral factors.

Sarcopenia Treatment
Drugs designed to treat sarcopenia are now starting to emerge. When considering the patients selected to enter studies of novel therapies to prevent or retard the development of sarcopenia, it is helpful to be aware of the industry regulatory processes surrounding drug development. Besides, the IOF has published recommendations specifically addressing the conduct of sarcopenia clinical trials and suggested possible trial endpoints and selection criteria for individuals who might participate in such studies.

Sarcopenia Treatment Market
Nutritional supplementation, resistance training, exercise, vibrational therapy constitute the treatment space for sarcopenia. Compared with singular interventions, combined interventions, including comprehensive exercise-based treatment interventions, such as resistance training and nutritional intervention, are effective for improving sarcopenia and are recommended.

Sarcopenia Market Insights
Assessment of the effect of interventions in research and clinical practice is required to enable them to be targeted appropriately. Unfortunately, no clear consensus has yet been reached regarding which intermediate measures should be used in research settings or clinical guidelines. The dynamics of sarcopenia market is anticipated to experience a positive shift in the coming years owing to the expected launch of BIO101 (Biophytis) and Bimagrumab (Novartis).

Do you know how the Sarcopenia market will grow by 2030? Click to get in-depth detail of the report- https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sarcopenia Market Drivers
• Better insights into disease intervention
• Increase in research initiatives
• Need for a cost-effective therapy

Sarcopenia Market Barriers
• Need for screening tools
• Implementation of interventions
• Diagnosis associated shortcomings

Sarcopenia Market Companies
• Biophytis
• Novartis
• Eli Lily
• Immunoforge
• Regeneron Pharmaceuticals
• Sanofi, and several others

Request Sample Report- https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Sarcopenia Executive Summary
3. Competitive Intelligence Analysis for Sarcopenia
4. Sarcopenia Market Overview at a Glance
5. Sarcopenia Disease Background and Overview
6. Patient Journey
7. Sarcopenia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Sarcopenia Unmet Needs
10. Key Endpoints of Sarcopenia Treatment
11. Sarcopenia Marketed Products
12. Sarcopenia Emerging Therapies
13. Sarcopenia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Sarcopenia Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Sarcopenia Market Drivers
19. Sarcopenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Sarcopenia Market Report Highlights
• In the coming years, the Sarcopenia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Sarcopenia. The launch of emerging therapies will significantly impact the Sarcopenia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Sarcopenia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Why should you buy this report?
• The report will help in developing business strategies by understanding trends shaping and driving the Sarcopenia market
• To understand the future market competition in the Sarcopenia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia market
• To understand the future market competition in the Sarcopenia market

Do you have any query related to the report? If yes, visit here- https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.